



November 13, 2020

MedVenture Partners, Inc.

Investment in Jmees, Inc.

MPI-2 Investment Limited Partnership (MPI), managed and operated by MedVenture Partners, Inc., has completed its Series A investment in Jmees, Inc.

Although laparoscopic surgery is becoming increasingly common, surgical outcomes rely heavily on the surgeon's experience. In many cases, intraoperative surgical complications such as unintended tissue damage can result in lower quality of life for the patient as well as increased medical costs. There are approximately 260,000 cases of such high-risk surgeries in Japan. However, there is currently no system available that sufficiently enables intraoperative real-time advanced imaging and intelligent analysis to address this issue.

Jmees is developing an artificial intelligence (AI) system to prevent intraoperative surgical complications and enhance patient safety in laparoscopic surgeries. The team originally spun out of a project developing other AI-assisted systems within National Cancer Center Hospital East and has been certified by the National Cancer Center ("NCC") as an official NCC startup.

MPI will not only financially support Jmees' product development, but will also name Hajime Oshita, President of MPI, to the Board of Directors to accelerate the development and marketing of their product.

MPI will continue to actively invest in the medical device space while accelerating the growth of medical device startups in Japan, bridging overseas startups and Japanese companies, and contributing to the development of a medical device ecosystem in Japan.

Press Contact:

Oriha Kuwaki

MedVenture Partners, Inc.

7F Nihonbashi Muromachi Mitsui Tower

Nihonbashi Muromachi 3-2-1 Chuo-ku, Tokyo 103-0022 JAPAN

Tel: +81-3-6273-4437